The COVID-19 pandemic has been particularly concerning and challenging for many cancer patients and their families. As you’ve most likely heard by now, cancer patients and survivors may be at higher risk of complications from COVID-19 because cancer and cancer treatments can contribute to weakened immune systems. This has left many patients with questions on how best to navigate their cancer care, including whether it is safe to continue their treatment, will their health care be de-prioritized by the healthcare system and how they can reduce their risk of contracting the virus.
Every year scientists, clinicians and patients from across the world gather to present and discuss the latest breast cancer research at the San Antonio Breast Cancer Symposium. We’ve gathered some highlights from 2019 conference:
We are all familiar with generics. The exact copy of the known chemical formula used in the original medicine is what constitutes the generic form of any medicine. There are multiple reasons why generics are able to be mass produced at a lower cost. An important step includes manufacturers of generics having to provide proof that their version is an exact copy of the chemical formula of the original medicine and that when used in healthy individuals, the metabolism remains very similar to the original compound. This shortened pathway of getting approved from Health Canada or a similar regulatory agency ensures less economic burden to manufacturers and provides the obvious advantage of a significantly lower price, as well as improved accessibility for patients.